Richard S Levy
CIK 1454983 · EVP, Chief Drug Dev Officer · last filed 2026-08-04
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$15.86M
Companies
6
Total Filings
106
Lifetime Open-Market Net
-$69.59M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KNSA | Director | 22,359 | $79.49 | $1.78M | $0 | 15 | 2026-08-04 |
| KOD | Director | 250 | $40.65 | $10.2K | $44.3K | 10 | 2026-07-02 |
| MDGL | Director | 22,469 | $524.37 | $11.78M | -$19.89M | 23 | 2026-06-18 |
| TARA | Director | 51,000 | $3.98 | $203.0K | $127.6K | 10 | 2026-06-16 |
| CONSTELLATION PHARMACEUTICALS INC (CNST) Delisted | Director | — | $33.99 | — | $0 | 2 | 2021-06-04 |
| INCY | EVP, Chief Drug Dev Officer | 16,926 | $123.47 | $2.09M | -$49.87M | 40 | 2016-01-08 |
Recent Filings · Page 2 of 11
106 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-14 | MDGL | Mixed | — | -$4.31M | EDGAR |
| 2025-11-13 | MDGL | Notice (144) | −8,500 | -$4.50M | EDGAR |
| 2025-07-03 | KNSA | Mixed | +1,101 | $0 | EDGAR |
| 2025-07-02 | KOD | Grant (A) | — | $0 | EDGAR |
| 2025-06-24 | MDGL | Grant (A) | +715 | $0 | EDGAR |
| 2025-06-13 | TARA | Grant (A) | — | $0 | EDGAR |
| 2025-06-05 | KNSA | Mixed | +3,173 | $0 | EDGAR |
| 2025-05-19 | TARA | Buy (P) | +20,000 | $63.8K | EDGAR |
| 2025-05-16 | TARA | Buy (P) | +20,000 | $63.8K | EDGAR |
| 2025-04-11 | MDGL | Exer (M) | +9,470 | $616.1K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.